Model ANV419 - Systemic no-alpha IL-2 Immunotherapy
The culmination of our research is ANV419, which is in clinical development. It is a rationally engineered fusion protein that is a stable, antibody-like molecule.
-
Most popular related searches
ANV419 is expected to
- Have better efficacy with excellent selectivity for CD8+ cells
- Result in better safety, no severe toxic events were observed in preclinical trials
- Require less frequent dosing as it is stable for longer in the body
Customer reviews
No reviews were found for Model ANV419 - Systemic no-alpha IL-2 Immunotherapy. Be the first to review!